Intensive behavioral therapy and liraglutide 3.0 mg show positive results for weight loss

February 24, 2020

SILVER SPRING, Md.--Intensive behavioral therapy (IBT) combined with liraglutide 3.0 mg (Saxenda) can produce clinically-meaningful weight loss in patients who receive the treatment in predominantly primary care settings, according to a study published online in Obesity, the flagship journal of The Obesity Society. The study is the first multi-site evaluation of the efficacy of IBT based on a treatment visit schedule covered by the Centers for Medicare and Medicaid Services (CMS).

"This is an impressive outcome, given the brief duration (15-minutes) of the counseling visits and the fact that participants were treated in a primary care setting, without the need to enroll in a group weight loss program at an academic medical center or another setting," said Thomas A. Wadden, PhD, professor of psychology in psychiatry, at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Wadden is the corresponding author of the study.

A total of 282 adults with obesity enrolled at 17 predominantly primary care clinics in the United States. All participants received 23, 15-minute, individual counseling sessions of IBT during a period of 56 weeks. The sessions were delivered by registered dietitians following a detailed treatment protocol.

After the first 28 weeks, participants assigned to IBT plus placebo lost an average of 5.4 percent of initial body weight, compared with a significantly larger loss of 8.4 percent for those who received IBT and liraglutide 3.0 mg; 44.3 percent and 69 percent of these participants, respectively, lost 5 percent or more of initial body weight--a common criterion of clinically-meaningful weight loss. At week 56, both groups regained a small amount of weight (from week 28) such that the mean weight loss for IBT plus placebo was 4 percent, compared with 7.4 percent for those treated by IBT and liraglutide 3.0 mg; 38.8 percent and 61.5 percent of these participants, respectively, lost greater than or equal to 5 percent of initial weight.

"These two treatment approaches, IBT and medication, appear to have complementary mechanisms of action," said Jena Shaw Tronieri, assistant professor of psychology in psychiatry at the Perelman School of Medicine and a colleague of Wadden's at the University of Pennsylvania's Center for Weight and Eating Disorders. Tronieri co-authored the study.

Weight loss in both treatment groups was associated with improvements in quality of life, as well as measures of cardiometabolic risk factors including waist circumference, triglyceride levels and hemoglobin A1c, a measure of blood glucose control.

As approved in 2011, Medicare beneficiaries with obesity--defined by a body mass index of 30 kg/m2 or greater--are eligible to receive IBT from a qualified health provider in a primary care setting. The CMS covers weekly brief 15-minute individual counseling sessions for the first month, and then sessions every other week for the next five months. Patients who lose 3 kilograms (6.6 pounds) or more are eligible for six additional monthly sessions.

Wadden encourages CMS to expand the range of practitioners who are eligible to provide IBT independently, which is currently limited to physicians, nurse practitioners, physician assistants and nurse specialists. At present, registered dietitians and other professionals may only provide IBT under the supervision of a primary care provider, such as a physician, who must be physically present on site when treatment is delivered.

"Registered dietitians, health counselors and other professionals could be trained to deliver IBT independently, which would help expand access to this critical intervention and, ultimately, help the millions of Americans who struggle with obesity and its associated health complications," said Wadden.

"Although this study provides important data on the feasibility of a dietitian-lead IBT in a primary care practice, these services that are covered by Medicare are rarely covered by any other insurance plan and the cost of implementing such a program is prohibitive for most private practice primary care providers," said W. Troy Donahoo, MD, FTOS, associate professor in the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, at the University of Florida. Donahoo was not associated with the research.

Donna Ryan, professor emerita at Pennington Biomedical Research Center in Baton Rouge, La., who was also not associated with the research noted "what is good about this study is that it shows that other office personnel besides the doctor can play an important role in weight management by delivering IBT. It is really important that we find ways to improve weight coaching--the essence of IBT--in primary care offices."
-end-
Other authors of the study include Danny Sugimoto of the Cedar Crosse Research Center in Chicago, Ill., Michael Taulo Lund, Pernille Auerbach, and Camilla Jensen of Novo Nordisk in Denmark and Domenica Rubino of the Washington Center for Weight Management and Research in Arlington, Va.

This study was designed, conducted, and sponsored by Novo Nordisk, while Wadden and Tronieri provided the IBT program implemented in the study. The IBT protocol was described previously in Obesity (October 2019, vol. 27, pages 1562-66) and is available online at http://www.med.upenn.edu/weight/wadden.html (under MODEL IBT Manual). Wadden served as principal investigator for the study site at the University of Pennsylvania.

Wadden serves on scientific advisory boards for Novo Nordisk and WW (formerly Weight Watchers). Tronieri serves as a consultant to Novo Nordisk, supervising dietitians who implement weight loss counseling in clinical trials that Novo Nordisk conducts.

The study, titled "Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial" will be published in the March 2020 print issue.

The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education, and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit http://www.obesity.org and connect with us on Facebook, Twitter and LinkedIn.

The Obesity Society

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.